Positive cream formulation results for SkinBiotix

RNS Number : 0875L

SkinBioTherapeutics PLC

17 April 2018

 

SkinBioTherapeutics plc

SkinBioTherapeutics' technology, SkinBiotix^®, shows positive results in cream formulation

Manchester, UK - 17 April 2018 - SkinBioTherapeutics plc (AIM: SBTX,  the "Company"), a life science company focused on skin health, announces that the 'cream' formulation of its SkinBiotix® technology has passed effectiveness studies in models of skin. The cream formulation will now undergo further testing for stability in the coming weeks.

SkinBioTherapeutics' platform, SkinBiotix®, utilises extracts of probiotic bacteria for application to the skin. The Company has shown in skin models that its technology can improve the skin's barrier function (e.g. keep moisture in and protect skin from infection).

The cream has been formulated to contain SkinBioTherapeutics' proprietary technology, SkinBiotix®. A crucial feature of the formulation phase is to test that the cream-SkinBiotix® combination retains the same beneficial properties as the original technology.

One important effect of SkinBiotix® in proof of concept studies was the increase of a specific skin protein essential to the barrier function of the skin. This effect was also shown when tested as a cream formulation. The data further showed a direct correlation between the amount of SkinBiotix® within the cream and the level of the protein present. Work on creating skin lotion and gel formulations is ongoing.

Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:

"The incorporation of our SkInBiotix® technology into an effective cream formulation is a major milestone in the development of products for the cosmetic market and, subject to stability testing, allows us to create formulations for our human study later this year."
 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company.

-Ends-

For more information, please contact:

SkinBioTherapeutics plc Dr. Cath O'Neill, CEO Doug Quinn, CFO	Tel: [phone]
Cairn Financial Advisers LLP (Nominated Adviser) Tony Rawlinson / Richard Nash	Tel: [phone]
Turner Pope Investments (Joint Broker) Ben Turner / James Pope Northland Capital Partners (Joint Broker) John Howes / Tom Price	Tel: [phone] Tel: [phone]
Instinctif Partners (Media Relations) Melanie Toyne-Sewell / Deborah Bell	Tel: [phone] [e-mail]

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin.  The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models.  Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. 

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

 

END

 

 

MSCGGUMGCUPRGQQ